SRH Wald-Klinikum Gera GmbH — Clinical Trial Site

49 Registered trials

21 Currently recruiting

Organisation

SRH Wald-Klinikum Gera GmbH

Location

Gera, Germany

Identifier

ORG-100025803

Address

Strasse Des Friedens 122, Debschwitz, 07548, Germany

Departments

-
--
2. Medizinische Klinik
98326005: Zentrum für klinische Studien
Brustzentrum
Brustzentrum Ostthüringen
Center for Clinical Studies
Clinic for Urology and Children Urology
Department of Gynecology and Obstetrics
Frauenklinik
Innere Medizin, Pneumologie, Hämatologie / Onkologie
Klinik für Hautkrankheiten und Allergologie
Klinik für Neurologie
Klinik für Pneumologie/Infektiologie, Hämatologie/Onkologie, Rheumatologie
Klinik für Pneumologie/Infektologie, Hämatologie/Onkologie
Medizinische Klinik
N/A
Oncology
Pneumologie/Infektiologie, Hämatologie/Onkologie, Rheumatologie
SRH Wald-Klinikum Gera GmbH
Zentrum fuer klinische Studien
Zentrum für klini sche Studien
Zentrum für klinische Studien

Clinical trials at this site (49)

Search interface

A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects with Moderate-t… Ended

2024-512496-12-00 Moderate to Severe Plaque Psoriasis 5 2025-04-01
CLINICAL STUDY TO TEST STEM CELLS FOR THE TREATMENT OF LONG-TERM, NON-HEALING VENOUS LEG ULCERS Ended

2024-512720-11-00 chronic venous ulcers (CVU) 5 2025-01-16
Phase 3 study of adjuvant V940 and Pembrolizumab in resected Stage II, IIIA, IIIB NSCLC Ended

2023-504923-20-00 Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer 5 2024-04-04
Phase 3 study of belzutifan plus pembrolizumab as adjuvant treatment in renal cell carcinoma (RCC) Ended

2023-505023-31-00 Renal cell carcinoma 5 2023-11-17
Phase 3 Study of V940 and Pembrolizumab in Resected Melanoma Ended

2023-503652-27-00 Melanoma 5 2023-10-06
Clinical Trial of MK-7684A with chemotherapy for extensive stage small cell lung cancer (ES-SCLC) Ended

2023-503517-30-00 Extensive-stage small-cell lung cancer 5 2022-04-01
Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended

2023-510390-33-00 HER2-negative breast cancer patients with high relapse 5 2020-10-23
Long-term study to assess the safety and efficacy of Nemolizumab in subjects with Atopic Dermatitis Ended

2024-514404-13-00 Atopic Dermatitis 5 2020-10-01
Efficacy Study of Nivolumab Compared to Placebo in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIB/C Melanoma (Ch… Ended

2022-502354-14-00 Completely resected Stage IIb/c melanoma 5 2019-10-28
Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma Ended

2022-501966-23-00 Resected High-Risk Stage II Melanoma 5 2018-09-11
Chemo +/- Pembrolizumab (MK-3475) as Perioperative Therapy for Stage II, IIIA-Resectable IIIB (N2) NSCLC Ended

2023-504820-24-00 Neoadjuvant/Adjuvant treatment for participants with Re 5 2018-03-21
Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended

2024-511096-15-00 Breast Cancer 5 2014-08-01
Assessment of the safety and effects on the body of investigational products when used on psoriatic skin Ended

2025-522446-51-00 Plaque psoriasis 3 2025-10-17
Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo®… Ended

2023-507865-24-00 Advanced (unresectable/metastatic) melanoma 5 2025-03-28
A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe … Ended

2024-511363-28-00 hidradenitis suppurativa (HS) 5 2024-09-24
A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 With a Randomized Withdrawal and Retreatment Period in Subject… Ended

2023-505842-24-00 Moderate to Severe Plaque Psoriasis 5 2024-05-07
A trial to evaluate the efficacy and safety of different doses of LEO 138559 in adults with moderate-to-severe atopic dermatitis. Ended

2022-500777-14-00 Atopic Dermatitis 4 2023-11-06
A Study Evaluating Pharmacokinetic Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Stage III and Stage IV … Ended

2022-502620-49-00 Resected Melanoma Stage III or Stage IV 2 2023-08-01
A study to test asundexian for preventing a stroke caused by a clot in participants after an acute ischemic stroke or after a high-risk tran… Ended

2023-503793-20-00 Prevention of ischemic stroke in patients post acute no 5 2023-01-18
Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination with Chemotherapy Versus Pembrolizumab Plus Chemotherapy as Fir… Ended

2023-506074-12-00 Metastatic Non-Small Cell Lung Cancer 5 2022-03-22
Adjuvant Immunotherapy with Nivolumab + Relatlimab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III… Ended

2023-507688-20-00 Participants with completely resected Stage III or Stag 5 2021-12-03
Study to investigate the efficacy and safety of allo-APZ2-CVU on wound healing of therapy-resistant chronic venous ulcer (CVU) Ended

2023-510162-27-00 Chronic venous ulcers (CVU) 4 2021-08-18
Pembrolizumab with Lenvatinib versus Docetaxel for Metastatic NSCLC after Platinum Doublet Chemotherapy and Immunotherapy Ended

2022-501439-18-00 NSCLC with squamous or nonsquamous histology 5 2019-06-26
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negati… Ended

2023-508472-11-00 Patients with early breast cancer 5 2018-06-13